title: The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE).
abstract: BACKGROUND
  Data evaluating the safety of using weight-based dosing of low-molecular-weight heparin (LMWH) in either underweight or obese patients with venous thromboembolism (VTE) are limited. Thus, recommendations based on evidence from clinical trials might not be suitable for patients with extreme body weight.
  
  
  METHODS
  Patients with objectively confirmed, symptomatic acute VTE are consecutively enrolled into the Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) registry. For this analysis, data from patients in the following ranges of body weight were examined: <50, 50-100, and >100 kg. Patient characteristics, underlying conditions, treatment schedules and clinical outcomes during the first 15 days of treatment were compared.
  
  
  RESULTS
  As of August 2004, 8845 patients with acute VTE were enrolled from 94 participating centers. Of these, 169 (1.9%) weighed <50 kg, 8382 (95%) weighed 50-100 kg and 294 (3.3%) weighed >100 kg. Patients weighing <50 kg were more commonly females, were taking non-steriodal antiinflammatory drugs (NSAIDs), and had severe underlying diseases more often than patients weighing 50-100 kg. Their incidence of overall bleeding complications was significantly higher than in patients weighing 50-100 kg (odds ratio 2.2; 95% CI: 1.2-4.0). Patients weighing >100 kg were younger, most commonly males, and had cancer less often than those weighing 50-100 kg. Incidences of recurrent VTE, fatal pulmonary embolism or major bleeding complications were similar in both groups.
  
  
  CONCLUSIONS
  Patients with VTE weighing <50 kg have a significantly higher rate of bleeding complications. The clinical outcome of patients weighing over 100 kg was not significantly different from that in patients weighing 50-100 kg.
authors.affiliation: Servicio de Medicina Interna, Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Barba
authors.forename: J
authors.initials: J
authors.lastname: Marco
authors.forename: H
authors.initials: H
authors.lastname: Martín-Alvarez
authors.forename: P
authors.initials: P
authors.lastname: Rondon
authors.forename: C
authors.initials: C
authors.lastname: Fernández-Capitan
authors.forename: F
authors.initials: F
authors.lastname: Garcia-Bragado
authors.forename: M
authors.initials: M
authors.lastname: Monreal
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology; D001835:Body Weight; D002986:Clinical Trials as Topic; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000401:mortality; D016017:Odds Ratio; D011655:Pulmonary Embolism / Q000150:complications / Q000401:mortality; D012042:Registries; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000906:Antibodies; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin